143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models
© 2023. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society..
The KRASG12C mutant has emerged as an important therapeutic target in recent years. Covalent inhibitors have shown promising antitumor activity against KRASG12C-mutant cancers in the clinic. In this study, a structure-based and focused chemical library analysis was performed, which led to the identification of 143D as a novel, highly potent and selective KRASG12C inhibitor. The antitumor efficacy of 143D in vitro and in vivo was comparable with that of AMG510 and of MRTX849, two well-characterized KRASG12C inhibitors. At low nanomolar concentrations, 143D showed biochemical and cellular potency for inhibiting the effects of the KRASG12C mutation. 143D selectively inhibited cell proliferation and induced G1-phase cell cycle arrest and apoptosis by downregulating KRASG12C-dependent signal transduction. Compared with MRTX849, 143D exhibited a longer half-life and higher maximum concentration (Cmax) and area under the curve (AUC) values in mouse models, as determined by tissue distribution assays. Additionally, 143D crossed the blood‒brain barrier. Treatment with 143D led to the sustained inhibition of KRAS signaling and tumor regression in KRASG12C-mutant tumors. Moreover, 143D combined with EGFR/MEK/ERK signaling inhibitors showed enhanced antitumor activity both in vitro and in vivo. Taken together, our findings indicate that 143D may be a promising drug candidate with favorable pharmaceutical properties for the treatment of cancers harboring the KRASG12C mutation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Acta pharmacologica Sinica - 44(2023), 7 vom: 01. Juli, Seite 1475-1486 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Lan-Song [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
143D |
|---|
| Anmerkungen: |
Date Completed 03.07.2023 Date Revised 04.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41401-023-01053-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352361921 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352361921 | ||
| 003 | DE-627 | ||
| 005 | 20231226053540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41401-023-01053-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352361921 | ||
| 035 | |a (NLM)36725884 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Lan-Song |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.07.2023 | ||
| 500 | |a Date Revised 04.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society. | ||
| 520 | |a The KRASG12C mutant has emerged as an important therapeutic target in recent years. Covalent inhibitors have shown promising antitumor activity against KRASG12C-mutant cancers in the clinic. In this study, a structure-based and focused chemical library analysis was performed, which led to the identification of 143D as a novel, highly potent and selective KRASG12C inhibitor. The antitumor efficacy of 143D in vitro and in vivo was comparable with that of AMG510 and of MRTX849, two well-characterized KRASG12C inhibitors. At low nanomolar concentrations, 143D showed biochemical and cellular potency for inhibiting the effects of the KRASG12C mutation. 143D selectively inhibited cell proliferation and induced G1-phase cell cycle arrest and apoptosis by downregulating KRASG12C-dependent signal transduction. Compared with MRTX849, 143D exhibited a longer half-life and higher maximum concentration (Cmax) and area under the curve (AUC) values in mouse models, as determined by tissue distribution assays. Additionally, 143D crossed the blood‒brain barrier. Treatment with 143D led to the sustained inhibition of KRAS signaling and tumor regression in KRASG12C-mutant tumors. Moreover, 143D combined with EGFR/MEK/ERK signaling inhibitors showed enhanced antitumor activity both in vitro and in vivo. Taken together, our findings indicate that 143D may be a promising drug candidate with favorable pharmaceutical properties for the treatment of cancers harboring the KRASG12C mutation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 143D | |
| 650 | 4 | |a KRASG12C | |
| 650 | 4 | |a MAPK signaling pathway | |
| 650 | 4 | |a small-molecule inhibitor | |
| 650 | 4 | |a synergistic effect | |
| 650 | 7 | |a adagrasib |2 NLM | |
| 650 | 7 | |a 8EOO6HQF8Y |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a Acetonitriles |2 NLM | |
| 700 | 1 | |a Zheng, Su-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Mei, Liang-He |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Ke-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ya-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Xiang-Tai |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Ming-Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Hua-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Cheng-Ying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmacologica Sinica |d 2000 |g 44(2023), 7 vom: 01. Juli, Seite 1475-1486 |w (DE-627)NLM111735181 |x 1745-7254 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2023 |g number:7 |g day:01 |g month:07 |g pages:1475-1486 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41401-023-01053-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2023 |e 7 |b 01 |c 07 |h 1475-1486 | ||